成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> Clinical Pharmacokinetics >>article
Clinical Pharmacokinetics

Clinical Pharmacokinetics

IF: 4.59
Download PDF

Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor.

Published:1 August 2023 DOI: 10.1007/s40262-023-01284-w PMID: 37493887
Neeraj Gupta, Michael J Hanley, Robert J Griffin, Pingkuan Zhang, Karthik Venkatakrishnan, Vikram Sinha

Abstract

Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor designed to overcome mechanisms of resistance associated with crizotinib, is approved for the treatment of ALK-positive advanced or metastatic non-small cell lung cancer. After oral administration of single doses of brigatinib 30-240 mg, the median time to reach maximum plasma concentration ranged from 1 to 4 h. In patients with advanced malignancies, brigatinib showed dose linearity over the dose range of 60-240 mg once daily. A high-fat meal had no clinically meaningful effect on systemic exposures of brigatinib (area under the plasma concentration-time curve); thus, brigatinib can be administered with or without food. In a population pharmacokinetic analysis, a three-compartment pharmacokinetic model with transit absorption compartments was found to adequately describe brigatinib pharmacokinetics. In addition, the population pharmacokinetic analyses showed that no dose adjustment is required based on body weight, age, race, sex, total bilirubin (

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Thiophene 110-02-1 C4H4S 444 suppliers $13.00-$945.95
Brigatinib 1197953-54-0 C29H39ClN7O2P 308 suppliers $5.00-$1504.50

Similar articles

IF:6.7

Phytochemicals: A potential next generation agent for radioprotection

Phytomedicine Bimal Prasad Jit , Subhaswaraj Pattnaik ,etc Published: 1 November 2022
IF:4.6

Clinical pharmacology of axitinib.

Clinical Pharmacokinetics Ying Chen, Michael A Tortorici,etc Published: 1 September 2013